Summary

Report Overview
Global Thyroid Gland Disorders Therapeutics Market reached US$ 2.7 billion in 2023 and is expected to reach US$ 4.3 billion by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031
Thyroid gland disorders therapeutics involve medical interventions to treat abnormalities in thyroid function, such as hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. Treatments include hormone replacement therapy, antithyroid medications, radioactive iodine, and surgical options. Advancements in molecular and targeted therapies improve treatment precision, providing more tailored solutions for patients. These treatments address metabolic imbalances caused by disrupted thyroid hormone production.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of thyroid disorders
The global thyroid gland disorders therapeutics market is experiencing growth due to the increasing prevalence of thyroid disorders like hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. Factors like aging populations, genetic predispositions, and autoimmune diseases like Hashimoto's thyroiditis and Graves' disease are contributing to this increase.
For instance, according to America Thyroid Association, over 12 percent of the U.S. population will develop a thyroid condition, with 20 Billion Americans having some form of thyroid disease. Up to 60% of those with thyroid disease are unaware of their condition. Women are five to eight times more likely than men to have thyroid problems. One woman in eight will develop a thyroid disorder.
Most thyroid cancers respond to treatment, but a small percentage can be aggressive. Undiagnosed thyroid disease can lead to serious conditions like cardiovascular diseases, osteoporosis, and infertility. Pregnant women with undiagnosed or inadequately treated hypothyroidism have an increased risk of miscarriage and preterm delivery.
Complications associated with the drugs
Thyroid gland disorders can result in various side effects, depending on the treatment. Hormone replacement therapy, used in hypothyroidism, can cause weight gain, hair loss, heart palpitations, anxiety, and insomnia. Antithyroid medications, like methimazole and propylthiouracil, can cause liver toxicity, skin rashes, joint pain, and reduced white blood cell counts, increasing the risk of infections. Radioactive iodine therapy can lead to long-term hypothyroidism, requiring lifelong hormone replacement, and may cause dry mouth, salivary gland inflammation, or taste changes.
Market Segment Analysis
The global thyroid gland disorders therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, and region.
The thyroid hormones from the drug class segment accounted for approximately 40.1% of the thyroid gland disorders therapeutics market share
The thyroid hormones from the drug class segment accounted for approximately 40.1%. Thyroid hormones are crucial in treating thyroid disorders, especially hypothyroidism. Hormone replacement therapies like levothyroxine are used to restore normal levels of thyroid hormones, regulating metabolism and energy levels.
The increasing prevalence of hypothyroidism and improved diagnostic techniques have driven demand for these therapies. Thyroid hormone levels are monitored and managed in patients undergoing treatments for hyperthyroidism, nodules, and thyroid cancer. The reliance on thyroid hormone replacement as a lifelong treatment contributes significantly to market growth.
For instance, in December 2023, the FDA approved 2 changes to the label of levothyroxine sodium (Tirosint-SOL, IBSA), an oral solution that is aimed to treat hypothyroidism. The first change included the use of levothyroxine sodium combined with proton pump inhibitor (PPI) therapy. The second change included timing to administer levothyroxine sodium.
Market Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increased prevalence, improved healthcare facilities, public awareness, and treatment options, as well as promotional strategies between governments and pharmaceutical companies.
For instance, in July 2024, the US Food and Drug Administration (FDA) granted full approval to the targeted therapy selpercatinib (Retevmo) for treating adult and pediatric patients 2 years and older with advanced or metastatic thyroid cancers that have certain changes in a gene called RET.
Market Segmentation
By Disease Type
Hypothyroidism
Hyperthyroidism
Others
By Drug Class
Thiourea derivatives
Propylthiouracil
Methimazole
Beta-adrenergic blocking agents
Propranolol
Others
Thyroid Hormones
Levothyroxine
Liothyronine
Others
Electrolytes
Potassium chloride
Others
Corticosteroids
Prednisone
Others
Tricyclic antidepressants
Amitriptyline
Others
Antiepileptic agents
Gabapentin
Others
By Route of Administration
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include GlaxoSmithKline PLC, Abbvie Inc,Amgen Inc, Novartis AG, Mylan NV, Merck KGaA, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Pharma (IBSA Group) among others.
Key Developments
In May 2023, Merck KGaA collaborated with the Executive Board of the Indonesian Medical Association and the Central Board of the Indonesian Thyroid Association to improve screening and diagnosis of thyroid disorders in Indonesia.
In December 2023, Aspen Pharmacare Holdings Limited made an agreement with Sandoz AG to acquire its Chinese business, helping to expand its presence in China by establishing a portfolio for future growth in the region.
Why Purchase the Report?
To visualize the global thyroid gland disorders therapeutics market segmentation based on disease type, drug class, route of administration, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the thyroid gland disorders therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global thyroid gland disorders therapeutics market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of thyroid disorders
4.1.1.2. Rise in the research and development
4.1.2. Restraints
4.1.2.1. Complications associated with the drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Disease Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Hypothyroidism*
6.2.1. Introduction
6.3. Hyperthyroidism
6.4. Others
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.2. Market Attractiveness Index, By Drug Class
7.3. Thiourea derivatives*
7.3.1. Introduction
7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Propylthiouracil
7.5. Thyroid Hormones
7.6. Electrolytes
7.7. Corticosteroids
7.8. Tricyclic antidepressants
7.9. Antiepileptic agents
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. GlaxoSmithKline PLC *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Abbvie Inc
12.3. Amgen Inc
12.4. Novartis AG
12.5. Mylan NV
12.6. Merck KGaA
12.7. Pfizer Inc
12.8. Takeda Pharmaceutical Company Limited
12.9. Elexis Inc
12.10. IBSA Pharma (IBSA Group) (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us